{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470611816
| IUPAC_name = (''S'')-10-[(dimethylamino)methyl]-4-ethyl-4,9-<br>dihydroxy-1''H''-pyrano[3',4':6,7]indolizino[1,2-''b'']<br>quinoline-3,14(4''H'',12''H'')-dione monohydrochloride
| image = Topotecan.svg

<!--Clinical data-->
| tradename = Hycamtin
| Drugs.com = {{drugs.com|monograph|topotecan-hydrochloride}}
| MedlinePlus = a610007
| pregnancy_category = D <small>([[Australia|Au]], [[United States|U.S.]])</small>
| legal_status = <U+211E>-only <small>(U.S.)</small>, [[Prescription drug|POM]] <small>([[United Kingdom|UK]])</small>
| routes_of_administration = [[Intravenous therapy|Intravenous infusion]], oral

<!--Pharmacokinetic data-->
| bioavailability = 31.4 % in humans [http://www.nature.com/clpt/journal/v76/n6/abs/clpt2004533a.html][http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=26&abstractID=2683]
| protein_bound = 35%
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 2-3 hours
| excretion = [[Kidney|Renal]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 123948-87-8
| CAS_supplemental = 119413-54-6 (hydrochloride)
| ATC_prefix = L01
| ATC_suffix = XX17
| PubChem = 60700
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB01030
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 54705
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7M7YKX2N15
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08618
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 84

<!--Chemical data-->
| C=23 | H=23 | N=3 | O=5 </sub><U+2022>HCl 
| molecular_weight = 457.9 [[Gram|g]]/[[Mole (unit)|mol]]
| smiles = O=C\1N4\C(=C/C2=C/1COC(=O)[C@]2(O)CC)c3nc5c(cc3C4)c(c(O)cc5)CN(C)C
| InChI = 1/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1
| InChIKey = UCFGDBYHRUNTLO-QHCPKHFHBX
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UCFGDBYHRUNTLO-QHCPKHFHSA-N
}}
'''Topotecan''' (trade name '''Hycamtin''') is a [[chemotherapeutic agent]] that is a [[topoisomerase inhibitor]].  It is a water-soluble derivative of [[camptothecin]]. It is used in form of the [[hydrochloride]] to treat [[ovarian cancer]] and [[lung cancer]], as well as other cancer types.

After GlaxoSmithKline received final FDA approval for Hycamtin Capsules on October 15, 2007, topotecan is the first topoisomerase inhibitor for oral use.

==Indications (approved uses)==
* [[Ovarian cancer]] (FDA May 1996).<ref>http://www.fda.gov/bbs/topics/NEWS/NEW00537.html</ref>
* [[Cervical cancer]] (FDA June 2006).<ref>http://www.cancer.gov/cancertopics/druginfo/fda-topotecan-hydrochloride </ref> <ref>http://www.fda.gov/CDER/Offices/OODP/whatsnew/topotecan.htm FDA</ref>
* [[Small cell lung cancer]] (SCLC) (FDA Oct 2007).<ref>http://onctalk.com/2007/12/18/oral-topotecan-fda-approved/</ref> <ref>http://www.drugs.com/newdrugs/gsk-receives-approval-hycamtin-topotecan-capsules-relapsed-small-cell-lung-cancer-671.html Press release</ref>

==Experimental use==
* [[Neuroblastoma]]
* [[Brainstem glioma]]

==Mode of action==
Hycamtin or topotecan is a semi-synthetic derivative of camptothecin.  Camptothecin is a natural product extracted from the bark of the tree ''Camptotheca acuminata''.  Topoisomerase-I is a nuclear enzyme that relieves torsional strain in [[DNA]] by opening single strand breaks.  Once topoisomerase-I creates a single strand break, the DNA can rotate in front of the advancing replication fork. Topotecan intercalates between DNA bases.  This intercalation disrupts the DNA duplication machinery when it reaches a site where topotecan is intercalated.  This disruption prevents DNA replication, and ultimately leads to cell death.  Mammalian cells cannot efficiently repair these double strand breaks.<ref>{{cite journal | doi = 10.1073/pnas.242259599  | author = Staker, B.L. et al | title = The mechanism of topoisomerase I poisoning by a camptothecin analog | year = 2002 | journal = PNAS | volume = 99 | issue = 24 | pages = 15387<U+2013>15392 }}</ref> This process leads to breaks in the DNA strand resulting in [[apoptosis]].

==Side effects==
*Myelosuppression
*Diarrhea
*Low blood counts
*Susceptibility to infection

==Generic versions==
Two generic versions have been approved in EU, and in Nov 2010 the US FDA approved a generic version.<ref>{{cite news |url=http://www.genengnews.com/gen-news-highlights/fda-rubber-stamps-app-pharma-s-generic-topotecan-for-small-cell-lung-and-cervical-cancers/81244300/ |title=FDA Rubber-Stamps APP Pharma<U+2019>s Generic Topotecan for Small Cell Lung and Cervical Cancers |date=30 Nov 2010 }}</ref>

==References==
{{reflist}}

==External links==
*[http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=41185 NCI Drug Dictionary Definition of Topotecan]
*[http://www.cancer.gov/cancertopics/druginfo/topotecanhydrochloride NCI Drug Information for Patients]
*[http://www.ovacome.org.uk/Ovariancancer/Treatment/Topotecanchemotherapy Use for ovarian cancer]


{{Chemotherapeutic agents}}

[[Category:Topoisomerase inhibitors]]
[[Category:Pyranoindolizinoquinolines]]
[[Category:Lactones]]
[[Category:Lactams]]

[[de:Topotecan]]
[[es:Topotec<U+00E1>n]]
[[fr:Topot<U+00E9>can]]
[[hr:Topotekan]]
[[nl:Topotecan]]
[[ru:<U+0422><U+043E><U+043F><U+043E><U+0442><U+0435><U+043A><U+0430><U+043D>]]
[[sr:Topotekan]]
[[fi:Topotekaani]]
[[zh:<U+6258><U+666E><U+6A02><U+80AF>]]
